Business
Adhera Therapeutics and Alyvant Enter into Digital Co-Promotion Agreement for Prestalia
Adhera Therapeutics and Alyvant Enter into Digital Co-Promotion Agreement for Prestalia.
About this update from Adhera Therapeutics Inc.
[{"type":"text","content":"RESEARCH TRIANGLE PARK, NC and NEW YORK, NY / ACCESSWIRE / March 4, 2019 / Adhera Therapeutics (OTCQB: ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and improve patient outcomes, and Alyvant, a company focused on tech-enabled pharma commercialization, today announced a digital co-promotion agreement for Prestalia®, an approved therapy for the treatment of hypertension. Robert Moscato, Jr., CEO of Adhera Therapeutics, commented, ''We are pleased to enter into a co-promotion agreement with Alyvant. The agreement affords Adhera the opportunity to increase the frequency of communication to healthcare providers and educate physicians beyond the reach of our sales team. Alyvant is a likeminded, data-driven company, and working together on Prestalia supports Adhera's mission of increasing drug adherence amongst our patients. We are delighted that Alyvant is co-promoting Prestalia and connecting patients to therapies that may benefit them through innovative uses of data and technology.'' Gillian Cannon, President of Alyvant, added, ''We are excited to partner with Adhera Therapeutics. Adhera's patient-centric treatment approach aligns well with Alyvant's targeted patient-level analytics approach. We anticipate the digital co-promotion will have a positive impact on the commercialization of Prestalia, and most importantly patients at risk of cardiovascular events who would benefit from taking this therapy.'' Dr. Cannon is an industry veteran with more than 30 years of experience in leadership roles at pharmaceutical companies including Merck, Otsuka and UCB. Alyvant's Chief Technology Officer, Mitchell Mittman, has held senior leadership roles in companies including Amazon, Expedia and Goldman Sachs, where he led the development of software and data science platforms.About Alyvant Alyvant uses de-identified patient-level analytics to better understand the nuances of a disease, patterns of physician prescription behavior, and payer reimbursement. We then turn insights into action through our fit-for-purpose commercial pharmaceutical organization. Alyvant's long-range vision is to use technology to reduce the cost of commercializing all medicines, thereby generating savings for the healthcare system at large and helping to ensure that every patient who might benefit from an approved ...